Comparison · NCT02096354-sae
RRx-001 Followed by Irinotecan vs Regorafenib Followed by Irinotecan: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RRx-001 Followed by Irinotecan vs Regorafenib Followed by Irinotecan: serious adverse events. Trial comparisons, record NCT02096354-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02096354-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.368 | 0.234 | 0.527 | wilson | |
| Risk in group 2 | 0.538 | 0.291 | 0.768 | wilson | |
| Risk difference, group 1 minus group 2 | -0.17 | -0.436 | 0.124 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.684 | 0.356 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.5 | 0.14 | 1.79 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on RRx-001 Followed by Irinotecan than on Regorafenib Followed by Irinotecan | 5.88 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RRx-001 Followed by Irinotecan | Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)~RRx-001~Irinotecan: To be dosed after RRx-001 or regorafenib | 14 | 38 | EG000 |
| Group 2 | Regorafenib Followed by Irinotecan | Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)~Regorafenib~Irinotecan: To be dosed after RRx-001 or regorafenib | 7 | 13 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Serious Adverse Events and **Other (Not Including Serious) Adverse Events** were collected beginning at baseline through end of treatment (28 days after last dose of study drug). All-Cause Mortality was assessed up to 47 months
Source ClinicalTrials.gov
Trial
- Title
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- NCT number
- NCT02096354
- Phases
- PHASE2
- Conditions
- Colorectal Neoplasms
- Interventions
- RRx-001, Regorafenib, Irinotecan
- Lead sponsor
- EpicentRx, Inc.
- Results first posted
- 2024-10-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02096354?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02096354-sae